Pembrolizumab plus chemotherapy in triple-negative breast cancer

Jun Masuda¹, Yukinori Ozaki², Fumikata Hara², Shigehisa Kitano³, Toshimi Takano²

Affiliations

¹ Department of Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan. Electronic address: jun.masuda@jfcr.or.jp.
² Department of Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
³ Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

PMID: 34217392
DOI: 10.1016/S0140-6736(21)00380-9

Comment

Pembrolizumab plus chemotherapy in triple-negative breast cancer

Jun Masuda et al. Lancet. 2021.

. 2021 Jul 3;398(10294):24.

doi: 10.1016/S0140-6736(21)00380-9.

Authors

Jun Masuda¹, Yukinori Ozaki², Fumikata Hara², Shigehisa Kitano³, Toshimi Takano²

Affiliations

¹ Department of Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan. Electronic address: jun.masuda@jfcr.or.jp.
² Department of Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
³ Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

PMID: 34217392
DOI: 10.1016/S0140-6736(21)00380-9

No abstract available

PubMed Disclaimer

Conflict of interest statement

A summary of competing interests is available in the appendix.

Comment in

Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply.
Cortes J, Rugo HS, Guo Z, Karantza V, Schmid P. Cortes J, et al. Lancet. 2021 Jul 3;398(10294):24-25. doi: 10.1016/S0140-6736(21)00374-3. Lancet. 2021. PMID: 34217393 No abstract available.

Comment on

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9. Lancet. 2020. PMID: 33278935 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pembrolizumab plus chemotherapy in triple-negative breast cancer

Affiliations

Pembrolizumab plus chemotherapy in triple-negative breast cancer

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources